Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Meiye Biotechnology
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Meiye Biotechnology is a Chinese biopharmaceutical company focused on the development of innovative metabolic and endocrine therapies. The company specializes in the discovery of small molecule and peptide-based treatments for prevalent conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). By leveraging advanced drug design and optimization techniques, Meiye Biotechnology aims to provide more effective and convenient therapeutic options for patients with metabolic disorders. The company is currently advancing several candidates through the pre-clinical stage, targeting well-validated pathways like the GLP-1 and GIP receptors.
- Therapeutic areas
- EndocrinologyGastroenterology
- Modalities
- Small moleculePeptides
- Industry
- Biotech
Beyond the preview
Go deeper on Shanghai Meiye Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Meiye Biotechnology.